Mika Health
- Company typePrivate
- Founded2017
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
Mika Health firmographics
Firmographics- Name
- Mika Health
- Legal name
- Outcomes4Me Germany GmbH
- Website
- https://de.mika.health
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mika Health industry classification
Industry- Product category
- Digital Therapeutics (Oncology)
- NAICS
- Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (621420)
- SIC
- Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
- akta.pro secondary industries
- Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where Mika Health is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Mika Health business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Others
Revenue model
- Freemium Patient App: The Mika app is provided free of charge to cancer patients. Patients download and use the app at no cost, with the app serving as the primary customer acquisition channel.
- Life Science Data Partnerships: Pharmaceutical and life science companies (AstraZeneca, Daiichi Sankyo, Recordati) partner with Mika to access anonymized patient data insights, optimize pharmacotherapies, and support patient education programs. Partners receive aggregated statistics on app usage and patient-reported outcomes.
- Healthcare Provider Partnerships: Collaborations with hospitals and cancer centers (Charité, University Hospital Leipzig, NCT Heidelberg) for clinical integration, research, and patient referrals. These partnerships may include data sharing agreements and co-development of content.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free for cancer patients - no cost to download or use |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Mika Health product offering
Product offeringCore offering
Mika Health develops and operates the Mika App, a CE-marked Class IIa certified digital therapeutic (DTx) for cancer patients, providing symptom and side effect tracking, medication reminders, AI-personalized educational content, and guideline-based psycho-oncological interventions. The companion Mika Krebs-Ratgeber (Cancer Guide) delivers expert-reviewed cancer information. The app is free to individual patients; monetization is driven by enterprise data and patient-support partnerships with pharmaceutical, life science, and healthcare organizations.
Product overview
Mika Health offers a portfolio of digital oncology support products centered on the Mika App, a CE-marked Class IIa certified digital therapeutic (DTx). The core Mika App provides cancer patients with symptom and side effect tracking, medication reminders, personalized psycho-oncological interventions, and evidence-based educational content. Complementing the app is the Mika Krebs-Ratgeber (Mika Cancer Guide), a separate information resource covering various cancer types. The company positions itself as Europe’s largest clinically-validated oncology DTx platform, supporting over 100,000 cancer patients since 2018. The offering is free for patients, with revenue derived from life science partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- Mika App The Mika App is a CE-marked Class IIa certified digital therapeutic (DTx) for cancer patients, available free of charge via Apple App Store and Google Play. It provides daily symptom and side effect tracking, medication and appointment reminders, personalized educational content adapted to cancer type and treatment phase, and guideline-based psycho-oncological journeys using CBT, ACT, relaxation, and coping techniques. Symptom diaries are exportable in FHIR format for sharing with oncology care teams.
- Mika Krebs-Ratgeber (Mika Cancer Guide) The Mika Krebs-Ratgeber is an expert-reviewed, evidence-based cancer information resource published on de.mika.health, covering breast cancer, prostate cancer, and other tumor types with articles on symptoms, diagnosis, types, and treatment options. It serves both as patient-facing cancer education and as content marketing that supports Mika App adoption and search-driven patient acquisition.
Quantifiable outcome
- 23% reduction in fatigue after 12 weeks of app use (pilot RCT at Charité Berlin)
- +4 more outcomes
Companies that use Mika Health
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Mika Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Mika Health partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- AstraZenecacoreMika Health collaborated with AstraZeneca and Daiichi Sankyo to deliver AI-enabled mobile support to women undergoing breast cancer treatment. The partnership provides patients with personalized digital therapeutic content and support integrated with their treatment journey.
- Daiichi SankyocoreJoint partnership with AstraZeneca and Mika Health for AI-enabled mobile support to breast cancer patients. Daiichi Sankyo contributes pharmaceutical expertise and patient access programs.
- Massive BiocoreCombination of AI and next-generation sequencing biomarker testing to empower cancer patients on treatment and those searching for or participating in clinical trials in the United States and Europe.
- Cancer Support CommunitycoreLaunch of United States' first AI-enabled 'Precision Support' digital therapeutic that is free for cancer patients. Aims to close gaps in mental health care for cancer patients through digital therapeutic intervention.
- Recordati Rare DiseasesminorPartnership to support patients with rare diseases, providing digital therapeutic tools and resources alongside Recordati's pharmaceutical treatments.
- Mount SinaicoreCollaboration with Mount Sinai cancer research and treatment institution for content development and clinical validation of digital therapeutic interventions.
- Charité BerlincoreCo-development of psycho-oncological content and clinical validation of the Mika app. Charité conducted pilot randomized controlled trials demonstrating app efficacy.
- University Hospital Leipzig (Universitätsklinikum Leipzig)coreClinical partnership for randomized controlled trial of Mika app, establishing clinical effectiveness for psycho-oncological treatment support.
- National Center for Tumor Diseases (NCT) HeidelbergcoreSOFIA (Mika) smartphone app trial for early detection of immune-related adverse events in patients receiving immune checkpoint inhibitors.
- University Hospital DüsseldorfminorCo-development partnership for digital therapeutic content and cancer patient support programs.
- Nationale Dekade gegen Krebs (National Decade Against Cancer)minorCollaboration as part of Germany's national cancer research initiative to improve cancer care and patient support.
- CancerXminorPartner in the White House-backed CancerX accelerator program for digital health innovation in cancer care.
- Dime SocietyminorCancer research organization partnership focused on diversity in medical research and patient support.
- Saarländische Krebsgesellschaft (Saarland Cancer Society)minorRegional cancer society partnership for patient education and support programs in the Saarland region of Germany.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Mika Health competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Mika Health social profiles
Digital presenceMika Health compliance and trust
Trust signalCompliance8 records
Mika Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mika Health leadership team
Management profileNumber of profiles
Profiles9 records
Mika Health funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mika Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mika Health
What does Mika Health do?
Mika Health develops and operates the Mika App, a CE-marked Class IIa certified digital therapeutic (DTx) for cancer patients, providing symptom and side effect tracking, medication reminders, AI-personalized educational content, and guideline-based psycho-oncological interventions. The companion Mika Krebs-Ratgeber (Cancer Guide) delivers expert-reviewed cancer information. The app is free to individual patients; monetization is driven by enterprise data and patient-support partnerships with pharmaceutical, life science, and healthcare organizations.
Is Mika Health a public or private company?
Mika Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mika Health founded?
Mika Health was founded in 2017. It employs 11 to 50 people.
Where is Mika Health based?
Mika Health is headquartered in Berlin, Germany, in the Europe region.
How does Mika Health make money?
Three revenue lines are on record. Freemium Patient App is the primary driver. The others are life Science Data Partnerships and healthcare Provider Partnerships.
Does Mika Health have an API?
No public API is recorded for Mika Health.
What industry is Mika Health in?
Mika Health's product category is Digital Therapeutics (Oncology). Its primary akta.pro industry code is HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation, with a secondary code of HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination). Its NAICS code is 621112 and its SIC code is 8000.